Uncategorized Archives

Reflecting on 2024 and Looking Ahead to 2025

2024: A Year of Transformation and Growth – Here’s What’s Next for Latica in 2025

As we close the chapter on 2024 and look toward the opportunities of 2025, I want to take a moment to reflect on an incredible year for Latica. It was a year of transformation, growth, and laying the groundwork for an even brighter future.

A Year of Transformation
The most visible change this year was our rebranding from Lynx.MD to Latica—a name that reflects our vision for the future of healthcare research. Deriving from the strong structural properties of a lattice, this new identity symbolizes the strength of data interconnectedness and our determination to maximize the value extracted by healthcare providers, researchers, AI companies and life science organizations from both structured and unstructured data.

While our name changed, our mission remained steadfast: to revolutionize healthcare through the power of connected data. We have never been more committed to breaking down silos, driving innovation, and improving outcomes for patients and providers worldwide.

Unprecedented Growth in 2024
This past year, we achieved incredible milestones:

Sales Expansion: 2024 saw a substantial expansion in our sales, with standout growth in data partnerships with some of the most innovative life sciences companies.
Expanding Networks: We solidified our position as leaders in GI and ENT, with impressive datasets that are driving research and AI development in these areas.
New Specialties: Beyond ENT and GI, we took significant steps into dermatology, creating new opportunities for collaboration and real-world evidence generation.
Strong Partnerships: Our growing collaborations with providers and life sciences organizations have amplified the impact of our platform on driving quality care and established Latica as a trusted partner in healthcare research.

These achievements reflect the dedication of our team and the strength of our partnerships, which are the backbone of our success.

What’s Next for 2025
As we look to 2025, we’re excited to build on this momentum with ambitious goals:

Driving Insights and AI Innovation: We’ll continue to enhance our platform’s capabilities, capitalizing on the wave of AI models with the unique data within our network, providing even deeper and more actionable insights for our partners.
Broadening Specialties: With robust ENT and GI networks in place, we’ll focus on strengthening these areas while advancing our work in dermatology and other specialties.
Collaborative Growth: Strengthening existing partnerships and forging new ones will remain central to our strategy as we empower life sciences companies with impactful data solutions.

A Heartfelt Thank You
To our team, partners, and clients: thank you for making 2024 a year to remember. Your trust, collaboration, and belief in our mission inspire us every day. Together, we’ve built a foundation for meaningful change in healthcare, and I am confident that 2025 will bring even greater achievements.

Here’s to another year of breaking barriers, driving innovation, and improving healthcare for all.

Warm regards,
Omer Dror
Founder & CEO, Latica

Lynx.MD is now Latica: A New Healthcare Ecosystem for Advanced Collaboration

We are excited to announce that Lynx.MD is now Latica! When we founded the company in 2019 we established a mission to transform the healthcare industry by providing the best-in-class secure data ecosystem, where data scientists leverage clinical and operational data to create innovative solutions that drive value and impact. While our mission remains unchanged, our new name reflects an expanded vision to transform the healthcare industry through the power of data and collaboration.

The name “Latica” embodies our vision and values, drawing inspiration from the interconnectedness and strength of a lattice structure. It represents the foundation of our company—a robust and interconnected network that amplifies healthcare data’s potential and fosters seamless collaboration. Additionally, derived from the Latin term “latus,” meaning “broad” or “wide,” it signifies our dedication to delving into the depths of previously inaccessible data to expand healthcare knowledge by unlocking the wealth of untapped data hidden within isolated infrastructures.

At the core of Latica’s founding lies an unwavering belief in the transformative power of data-driven insights. Recognizing the need for collaboration and synergy among various healthcare stakeholders, Latica set out to create an advanced platform that effortlessly connects healthcare providers, bio, medtech and other research organizations to advance medicine through data. This innovative ecosystem fosters collaboration, knowledge exchange, and shared discoveries, powered by state-of-the-art artificial intelligence and natural language capabilities.

By harnessing the collective expertise within this interconnected network, Latica aims to drive breakthroughs in medical research, optimize treatment protocols, and catalyze transformative changes in healthcare delivery.

With our cutting-edge platform, healthcare organizations gain secure access to a centralized, permissioned, controlled environment where they can confidently share data to advance new developments in healthcare.

Our platform empowers collaborative analytics, research, and development while prioritizing security and patient privacy. By integrating advanced data analytics, machine learning, and natural language processing, Latica extracts valuable insights from both structured and unstructured data, enabling providers and researchers to drive transformative advancements.

Data investigators benefit immensely from Latica’s platform, gaining unparalleled access to diverse datasets that accelerate discoveries and foster groundbreaking advancements. They can explore new frontiers of knowledge, uncover hidden patterns that pave the way for new therapies and improved patient care.

In addition to the ability to contribute data for medical research, healthcare administrators gain powerful tools that can be used to optimize resource allocation, streamline operations, and improve overall efficiency in healthcare delivery. With enhanced visibility and insights, administrators can make informed decisions that positively impact patient outcomes while optimizing the utilization of resources.

By spearheading this transformative journey, we empower providers and researchers to unlock the full potential of interconnected data, revolutionizing healthcare and improving the lives of all.
At Latica, we firmly believe in the transformative power of data. We are dedicated to forging strong partnerships, combining our expertise with yours to unlock endless possibilities. Together, let’s pave the way for a better healthcare future informed by data.

Sincerely,
The Latica Team

Beyond Skin Deep: How Data Connects Autoimmune Diseases for Better Treatments

Author: Omer Dror, CEO & Co-Founder

When founding Latica, I was constantly haunted by the questions: How can data help bring truly impactful treatments to market faster while ensuring their long-term success and positive outcomes? How do we leverage data to accelerate progress in healthcare? I naturally believe the answer lies in the data, but what I’ve come to know is that in many cases, pulling together real-world data (RWD) from seemingly disparate fields like dermatology, gastroenterology, and otolaryngology can tell a more accurate story.

The Immunological Connection: Why These Fields Hold the Key

The success of this approach lies in the surprising interconnectedness of chronic illnesses, revealing a common thread – immunology and the resulting inflammation. Disruptions in the immune system play a significant role in the development of conditions like psoriasis, inflammatory bowel disease (IBD), and chronic rhinosinusitis (CRS). This overlap presents a golden opportunity: by collecting longitudinal RWD – patient data gathered over an extended period – we can identify shared biomarkers and treatment targets across these conditions.

The Financial Burden of Autoimmune Diseases

The economic impact of autoimmune diseases is staggering. According to the American Autoimmune Related Diseases Association (AARDA), the annual direct healthcare costs associated with autoimmune diseases exceed $100 billion in the United States alone. This figure likely underestimates the true cost, as it only accounts for seven of the more than 100 known autoimmune diseases. When considering all autoimmune conditions, the total annual cost could potentially reach $300 billion.

Let’s break down the costs for some specific autoimmune and allergic/inflammatory conditions:

Rheumatoid Arthritis (RA): The annual direct cost of treating RA in the US is estimated at $10.9 billion, with indirect costs totaling $8.4 billion. Some studies suggest the total cost could be as high as $16 billion to $47.6 billion annually.
Psoriasis: With approximately 9 million affected individuals in the US, the annual cost of psoriasis treatment ranges from $51.6 to $63.2 billion. Monthly costs for topical treatments can average upwards of $600, while annual biologic costs can range from $40,000 to $50,000 per patient.
Multiple Sclerosis (MS): The estimated annual cost for MS treatment in the US is $63.3 billion.
Add ibd, asthma

Beyond the Finish Line: The Untapped Value of Post-Approval RWD

The traditional drug development model often overlooks a crucial phase: what happens after a drug receives FDA approval? This is where RWD shines. Here’s why:

Unveiling the Real-World Picture: Clinical trials offer a controlled environment, but they don’t capture the complexities of real-world use. RWD paints a more holistic picture, revealing how patients respond to treatments in their everyday lives, including potential side effects and long-term efficacy.

Precision Medicine Takes Flight: Imagine tailoring treatment plans not just to a primary condition, but to a patient’s unique profile across specialties. Diverse RWD empowers this kind of personalized approach, potentially leading to improved outcomes and reduced healthcare costs.

The Economic Impact of Early Diagnosis and Treatment

Early diagnosis and treatment of autoimmune diseases can significantly reduce healthcare costs. For example, studies have shown that RA patients miss an average of 7.92 work days per year compared to 4.34 days for individuals without RA. By identifying and treating these conditions earlier, we can potentially reduce both direct medical costs and indirect costs associated with lost productivity.

Turning the Tide: Overcoming Challenges

Of course, there are challenges. Integrating data across specialties, ensuring patient privacy, and utilizing notes that contain crucial insight into the patient experience, disease severity, and clinical outcomes require focused efforts. However, the potential rewards far outweigh the hurdles.

The Future is Connected: Seizing the Opportunity

By embracing RWD we can unlock a new era of post-approval success. Imagine a future where data is used for precision targeting of patients most likely to respond to a given treatment and clinical pathways are continuously refined based on real-world data, leading to better patient outcomes, less switching of treatments, and reduced cost. This is the power of connecting data, and those who recognize its potential will be at the forefront of the next wave of medical innovation.

The call to action is clear: Let’s leverage the power of RWD to bridge the gap between approval and long-term success. Together, we can ensure that our innovations not only reach the market faster but also deliver on their promise to improve patients’ lives in the long run while potentially reducing the enormous financial burden of autoimmune diseases on our healthcare system.

Reference Sources

General Cost of Autoimmune Diseases: The American Autoimmune Related Diseases Association (AARDA) reports that the annual direct healthcare costs associated with autoimmune diseases exceed $100 billion in the U.S. This figure is likely an understatement, as it only accounts for seven of the more than 100 known autoimmune diseases, with the total costs potentially reaching $300 billion annually.

Rheumatoid Arthritis (RA): The direct cost of treating RA in the U.S. is estimated at $10.9 billion, with indirect costs totaling $8.4 billion. Some estimates suggest that the total cost could range between $16 billion and $47.6 billion annually.

Psoriasis: The annual cost of psoriasis treatment is estimated to range from $51.6 billion to $63.2 billion. Monthly costs for topical treatments can average upwards of $600, while annual biologic treatment costs range from $40,000 to $50,000 per patient.

Multiple Sclerosis (MS): The estimated annual cost for MS treatment in the U.S. is approximately $63.3 billion.

Economic Impact of Early Diagnosis and Treatment: Studies have shown that patients with RA miss an average of 7.92 workdays per year compared to 4.34 days for individuals without RA, highlighting the indirect costs associated with lost productivity.

Fall into Innovation: Latica Gears Up for Life Science – MedTech Conference Season

Author: Collin Labar

Looking Ahead to Fall 2024 🍁 Life Science Events

Fall is not just the season of football, cooling temperatures, and everything Pumpkin Spice-related. It is a time of discovery in the Life Science and MedTech world. Conferences like MedTechX, ARS 2024, HLTH, DIA Real-World Evidence, and ISPOR Europe draw the brightest minds – researchers, data scientists, informaticists, market access experts, and medical affairs teams – eager to explore the cutting-edge technologies that will revolutionize the way we develop, launch, and monitor therapies.

At Latica, we’re particularly excited about the role Artificial Intelligence (AI) and Large Language Models (LLMs) are playing in this transformative journey. These technologies are fueling significant advancements in real-world data analysis, a crucial aspect of drug development and post-market surveillance.

As we head towards these industry gatherings, here’s what we at Latica are excited about:

Poster Presentations: Partnering with industry leaders, we’ll be showcasing insightful research based on real-world data that has only recently been available via Latica Technology.
Real-World Data Research Collaboration: We’re looking forward to collaborating with partners to define innovative research projects for 2025 that leverage Latica’s extensive RWD dataset. Our platform and partnerships create a unique data resource powered by over 175 million real-world patient encounters and millions of valuable unstructured data points, providing a powerful platform for groundbreaking discoveries.

Ready to Leverage Real-World Data for Success?

Latica offers a comprehensive solution for harnessing the power of real-world data.

We’d love to meet you at one of these industry events for coffee and data-driven conversations.

Connect with us on LinkedIn or use the Contact Us link to learn more about how to achieve breakthrough results and develop impactful research for future events.

Don’t miss the opportunity to revolutionize your approach to medical activities, drug development, and market access this fall! 🍁🍂🎃 🏈

The Common Factor Between Gastroenterology, Dermatology and ENT/Allergy Diseases

Author: Dr. Robert Eisdorfer, Latica chief medical officer and co-founder

The Shared Language of Immunology

At first glance, Gastroenterology, Dermatology, and ENT/Allergy appear to have little in common. As a cornerstone of Latica’s data and analytics strategy, further explanation should be helpful.

People with seemingly unrelated diseases can have similar experiences because of one common factor: excessive type 2 inflammation, which in itself is part of a normal immune response to allergens and infections. However, when it goes into overdrive, it can contribute to inflammatory diseases such as asthma, atopic dermatitis (eczema), chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis (a chronic and progressive digestive disease), or even certain environmental allergies. Treatments directed at certain interleukins (ie. IL-12, IL-23 etc)work in a variety of disease states including:

Asthma
Atopic Dermatitis (AD)
Nasal Polyps (NP), or Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
Eosinophilic Esophagitis (EoE)
Prurigo Nodularis (PN)
Certain Food Allergies

Other types of inflammation result in diseases like IBD and psoriasis, and again treatments overlap specialty disciplines.

From a real-world data (RWD) perspective, large data sets plus predictive analytics and machine learning should enable crucial insights. The correct drug at the right time and dose for each patient, and evaluation of response and natural history in people with more than one disease (ie. eosinophilic esophagitis and asthma).

Large data sets have already provided insights into the natural history of crs with np, selection and dosing of biologics in different pt populations in IBD. Using LLM’s, images, and videos, along with longitudinal real world data will provide increased understanding of multiple inflammatory and immunologic diseases.

Explore Real-World Data With Latica

Explore how Latica’s AI-powered platform can revolutionize your approach to life science research with domain expertise in gastroenterology, otolaryngology, dermatology, and more.

Contact us today to learn about our data resources and industry-leading platform.

About the Author

Dr. Robert Eisdorfer, Chief Medical Officer and co-founder of Latica is a Gastroenterology Specialist with over 38 years of experience in the medical field. He is passionate about advancing medicine and improving patient outcomes through the application of meaningful medical research and technology. Dr. Eisdorfer works with healthcare organizations around the world to provide strategic guidance for the consideration and adoption of new technology solutions.

From a Small Startup to a Data-Rich Dream Job: My Journey as a Bioinformatics Data Scientist

Author: Yael Silberberg, VP Data Science, Latica

Overcoming the Challenges of Traditional Data

As a bioinformatics data scientist, I’ve spent years in the trenches of medical research. One of them was working at a small startup that aimed to find the best treatments for cancer based on biopsy results. In that role, the process was meticulous and slow—each study required us to carefully design a protocol, recruit patients with specific indications, and wait for months to determine whether the treatment was effective. We collected data painstakingly, one patient at a time, over long periods. This is still the case for many diagnostic startups and even large pharmaceutical companies, where every new patient adds a valuable data point, but progress is often measured in small, incremental steps.

A Paradigm Shift: The Power of Pre-Existing Data

When I moved to my new role, the first thing that blew my mind was the sheer volume and accessibility of the data. All the information we had slowly accumulated in my previous job—biopsy images, treatment plans, patient responses—was already here, waiting to be analyzed. And not just for a few patients, but for thousands, across a wide range of indications. It felt like stepping into a researcher’s dream.

While retrospective data should never fully replace the rigor of prospective data, where hypotheses are tested in real time, the ability to rapidly generate and test new hypotheses using pre-existing data is a game-changer. Instead of waiting for months or years to gather enough data to draw meaningful conclusions, I can now leverage vast datasets that span different providers, countries, indications, and populations. The potential to validate findings across multiple datasets, in a fraction of the time it would take in a traditional research setting, is nothing short of revolutionary.

The Impact on Medical Research

This transition has opened my eyes to the incredible possibilities that come with having access to such rich, diverse datasets. Here are just a few ways in which this data is transforming the research landscape:

Accelerating Hypothesis Generation and Testing: In the traditional research model, formulating and testing a hypothesis could take years. With the data now at our disposal, hypotheses can be generated and tested almost as quickly as we can code. This rapid iteration process allows us to explore a wide array of potential treatments and diagnostic markers, refining our understanding at an unprecedented pace.
Enhancing the Power of Retrospective Analysis: While prospective studies remain the gold standard, retrospective analysis using large datasets offers a powerful complement. By analyzing existing data, we can identify patterns and correlations that might not be apparent in smaller studies. Finding new biomarkers that were not even collected in traditional studies. This can inform the design of future prospective studies, making them more focused and effective.
Validating Across Diverse Populations: One of the biggest challenges in medical research is ensuring that findings are applicable across different populations and centers. With access to data from multiple providers and countries, we can validate our hypotheses in diverse patient populations. This not only increases the robustness of our findings but also ensures that treatments are more universally effective.
Streamlining Phase 4 Clinical Studies: Traditionally, Phase 4 clinical studies, which assess the long-term side effects of new drugs, are lengthy and resource-intensive. By leveraging existing data, we can conduct these studies more efficiently, monitoring patient outcomes over extended periods and identifying long-term adverse effects more quickly and without opening a new study, only by analyzing the data that is collected anyway in the clinics .

Challenges and Opportunities

Of course, there are many challenges that come with working with such vast datasets. Data quality, integration across different sources, and ensuring patient privacy are just a few of the hurdles we face. However, these challenges are far outweighed by the opportunities. Having access to this data is the dream of any researcher, offering a chance to make meaningful discoveries that can transform patient care.

The Dream of Every Researcher Reflecting on my journey from a small startup to my current role, I can’t help but feel a sense of excitement and possibility. The transition has not only expanded my access to data but has also broadened my perspective on what’s possible in medical research. The ability to work with such a rich, diverse dataset is something I could only dream of in my previous roles, and I am eager to see how this data will continue to drive innovation and improve patient outcomes in the years to come.

About the Author

In addition to her work with Latica, Yael is also the Director of Computational Biology at Point6 Bio, where she has been leading research since March 2024. With over a decade of experience in data science and bioinformatics, Yael has held senior roles at Pyxis Diagnostics, including VP of Data Science, and at BiomX Ltd, where she served as Head of Data Science. Her expertise spans big data analytics, computational biology, and bioinformatics, honed through her academic journey at Tel Aviv University, where she earned a PhD in Bioinformatics.

Explore how Latica’s AI-powered platform can revolutionize your approach to life science research. Contact us today to learn more about our data resources and industry-leading platform.

Learn from Israeli Healthcare’s Real-World Data Initatives

Author: Latica

The Israeli healthcare system is leading medical research and innovation through partnerships with Latica, a medical data intelligence platform. Israel’s biggest healthcare providers: the Government Medical Centers Division of the Israeli Ministry of Health and Clalit Health Services are advancing key strategic data initiatives and leverage secure real-world data sharing to improve patient outcomes.

Unlocking the Power of Real-World Data for Strategic Initiatives

For years, fragmented healthcare data systems and privacy concerns hampered efforts to use real-world data for strategic initiatives. Latica’s platform bridges this gap. By providing a secure and controlled environment for anonymized data sharing, Latica empowers healthcare providers to:

Fuel Medical Research and Development: The Kineret Project exemplifies this. Latica integrates with a vast database of patient information, allowing researchers to mine valuable insights for developing new treatments and improving healthcare delivery.
Enhance Population Health Management: Clalit Health Services, through its partnership with Latica, can leverage real-world data to identify at-risk populations and tailor preventive care programs. This proactive approach improves overall population health outcomes.
Optimize Clinical Decision-Making: Access to anonymized patient data through Latica empowers clinicians to make data-driven decisions at the point of care, potentially leading to better treatment plans and improved patient outcomes.

Measurable Results: A Win for All

The partnerships between Latica and the Israeli healthcare providers have yielded demonstrably positive results. Both Clalit Health Services and the Government Medical Centers Division have leveraged the platform to:

Increase Internal Research Projects: The secure and user-friendly platform has streamlined internal research efforts, enabling healthcare providers to initiate and complete a significantly higher number of in-house research projects.
Scale Up External Research Partnerships: Latica has facilitated a dramatic increase in the number of external research partnerships for both providers. The platform allows both provider organizations to securely partner with life science and academic researchers to securely access anonymized data, accelerating collaboration and innovation.

Secure Real-World Data Sharing: A Key to Success

The foundation of these successful partnerships lies in Latica’s secure real-world data sharing capabilities.

Data Anonymization: Patient privacy remains paramount. In the case of Kineret and Clalit, they are taking the lead on all de-identification of data before granting permissioned researchers to work with the data. For other Latica partners the Latica platform ensures sensitive data is anonymized before being accessed protecting patient identities while enabling valuable research and analysis.
Granular Access Control: Healthcare providers retain complete control over their data. The Latica platform allows the provider organization to grant granular access permissions to researchers and institutions, ensuring data is used only for approved purposes.
Robust Security Protocols: Latica adheres to the strictest security protocols, safeguarding sensitive healthcare data and ensuring compliance with regulations.

A Bright Future for Healthcare

The collaborations between Latica, the Israeli Ministry of Health, and Clalit Health Services create opportunities to advance healthcare discovery informed by real-world data. By addressing strategic data initiatives and leveraging secure real-world data sharing, these partnerships pave the way for a future filled with groundbreaking discoveries, improved population health management, and ultimately, better patient outcomes.

Meet Your Strategic Data Goals

Contact Latica today to discuss how our industry-leading platform can support your strategic data initiatives and clinical research goals.

Real-World Data’s Role in Advancing MASH Treatment

Author: Collin Labar

The recent market entry of Madrigal Pharmaceuticals Rezdiffra¹, a groundbreaking treatment for metabolic dysfunction-associated steatohepatitis (MASH), marks a significant milestone in gastroenterology care. While this achievement is undoubtedly a testament to the power of pharmaceutical innovation, it also underscores the critical role of technology and real-world data (RWD) in accelerating drug development and optimizing patient outcomes.

As a healthcare data technology company, we are excited to see how advanced technologies and RWD have enabled the rapid progression of Rezdiffra from the clinical trial phase to market approval. These tools have been instrumental in enhancing our industry understanding of MASH and other gastrointestinal diseases, paving the way for developing new and effective therapies. Much of the value is contained in the data itself, and emerging technologies now allow for the rapid extraction of real-time clinical outcomes locked in physician notes, procedure reports, imaging, lab results, and pathology data.

The Journey Ahead: Market Surveillance and Real-World Evidence

According to BioPharma Dive Rezdiffra has made a remarkable entry into the market, generating $14.6 million in U.S. sales within its first months. This performance has exceeded Wall Street analysts’ expectations and set the stage for potential European commercialization. The drug’s approval is based on its efficacy in improving liver fibrosis and resolving MASH in patients with moderate to advanced liver fibrosis, without requiring invasive liver biopsies for diagnosis.

As Rezdiffra, or any new drug, becomes more widely available, it is essential to closely monitor its performance in the real world to fully understand its impact on patient outcomes. This is where technology and RWD will continue to play a pivotal role.

Real-world evidence generation: By leveraging robust data collection and analysis platforms, we can gather comprehensive information on treatment patterns, patient adherence, and real-world effectiveness. This data will be invaluable in identifying potential safety concerns, optimizing treatment strategies, and demonstrating the long-term value of therapeutics after entering the market.
Patient experience monitoring: Technology can be used to capture patient-reported outcomes and feedback in real-time, providing insights into the overall treatment experience. This information can help identify areas for improvement in care delivery and patient support services.
Identifying emerging trends: Advanced analytics can be applied to RWD to uncover new insights into MASH disease progression, patient populations, and treatment response. These findings can inform future research and development efforts.
Data-driven decision making: Real-world evidence is increasingly informing regulatory decisions and post-market surveillance. Given the large number of people waiting for this first-in-class option, it will inform patient selection for treatment.

By harnessing the power of technology and RWD, the industry can continuously monitor, refine understanding, and optimize the care provided to MASH patients. This data-driven approach will not only ensure the successful commercialization of Rezdiffra but also drive innovation in gastroenterology and other MASH-focused therapies.

Contact us today to explore how Latica’s AI-powered platform can revolutionize your approach to life science and MedTech research.

Note: This blog post is for informational purposes only and does not constitute any endorsement or affiliation with any specific pharmaceutical company or treatment. It is intended to provide general industry insights on the use of technology and real-world data in the healthcare and pharmaceutical research lifecycle.

Claims Generate Claims. Latica Generates Answers.

Author: Latica

Real-World Evidence For MedTech and Life Sciences

The post-FDA approval environment is undergoing a transformative shift, driven by the increasing importance of real-world evidence (RWE). While randomized controlled trials (RCTs) have been foundational in drug and device development, their limitations in capturing real-world patient experiences have become increasingly apparent. RWE, derived from real-world healthcare data, offers a vital perspective on product performance in the market, empowering medical affairs and market access teams to make informed decisions that benefit patients.

To fully realize the potential of RWE, it is essential to look beyond traditional structured data sources. While valuable, structured data such as electronic health records (EHRs) and claims databases often fall short of capturing the nuances of real-world clinical practice. The untapped wealth of unstructured data, including clinical notes, imaging reports, and patient-generated health data, holds the key to unlocking a deeper understanding on how well therapies perform after receiving FDA approval and in-market.

Here’s how RWE unlocks this potential:

Beyond Structured Data: The Power of Unstructured RWE

Unstructured data offers a rich, narrative-based perspective on patient experiences, treatment decisions, and outcomes. By leveraging advanced analytics and natural language processing (NLP), organizations can extract valuable insights that are often hidden within the text of clinical records. These insights can be used to:

Enhance Product Understanding: Unstructured data provides a deeper understanding of how products are used in real-world settings, including off-label use, treatment patterns, and patient adherence.
Identify Safety Signals: Early detection of adverse events can be facilitated by analyzing unstructured data for patterns and trends.
Inform Product Development: By understanding patient experiences and unmet needs, companies can identify opportunities for product improvement and innovation.

Driving Market Access and Medical Affairs Success

For market access teams, unstructured RWE can be used to:

Develop Compelling Value Propositions: Demonstrate real-world effectiveness and impact on cost of care to build robust value propositions for payers and healthcare providers. Uncover evidence of improved patient outcomes, quality of life, and resource utilization to differentiate the product.
Optimize Pricing and Reimbursement Strategies: Inform pricing and reimbursement strategies by demonstrating the product’s real-world value and impact on cost of care. Utilize unstructured data to quantify cost-effectiveness and support negotiations with payers.

Medical affairs teams can leverage unstructured RWE to:

Enhance scientific understanding: Delve deeper into product mechanisms of action, safety profiles, and real-world effectiveness through in-depth analysis of unstructured data.
Inform medical strategy: Identify emerging trends, unmet medical needs, and opportunities for clinical development by analyzing real-world clinical practice.
Support evidence generation: Generate high-quality real-world evidence publications to strengthen the product’s scientific foundation and inform healthcare decision-making.
Optimize medical communications: Tailor messaging and materials to address healthcare provider needs and concerns based on insights from real-world data.

Overcoming Challenges and Maximizing RWE Potential

To fully realize the benefits of unstructured RWE, organizations must invest in advanced analytics capabilities, data privacy and security measures, and skilled personnel. Collaboration between market access, medical affairs, and data science teams is essential for successful RWE initiatives.

By embracing the power of unstructured data, the pharmaceutical and medical device industries can unlock new opportunities for post-approval success, improve patient outcomes, and strengthen their market positions.

Harnessing the Power of AI and Machine Learning

While unstructured data offers a goldmine of insights, manually analyzing it can be time-consuming and resource-intensive. This is where the Latica platform comes in. With Latica artificial intelligence (AI), natural language processing (NLP), and computer vision, deep insights can be extrapolated efficiently from complex data sources.

AI and NLP can automate the extraction of key data points from unstructured sources like physician notes, PDFs, procedure/pathology reports, and patient surveys. This data can then be used to build robust value propositions for payers and healthcare providers. Imagine AI automatically highlighting sections of clinical notes that discuss improved patient outcomes or cost savings, or pathology finding, empowering teams to focus their efforts on these impactful areas.
- In a recent Latica use case, a drug manufacturer needed to identify patient care flow and unmet needs using information that could only be obtained from clinical notes. Latica’s AI was able to determine whether specific assessments were performed and what factors led to drug switches, providing crucial insights for the manufacturer’s strategy
Computer vision can analyze medical images to quantify disease progression and assess treatment efficacy in real-world settings. This data can be used to support product claims and demonstrate real-world value.
- Latica’s AI and computer vision has been instrumental in gastrointestinal health care. Analyzing colonoscopy imaging and associated reports to detect adenomas can only be done effectively with AI and computer vision. Latica’s advanced algorithms can extract these critical insights, enabling researchers to improve early detection rates and treatment outcomes

The Future of Medical Affairs and Market Access

The future of healthcare hinges on understanding the real-world impact of treatments. By harnessing the combined power of traditional data, rich patient experiences, and cutting-edge AI, medical affairs and market access teams can revolutionize how they assess medical devices and therapies.

Latica leverages advanced AI/ML and Computer Vision to break down data silos by providing a comprehensive platform that captures the full patient experience through both structured and unstructured data. This empowers medical affairs and market access teams to accelerate the delivery of life-changing treatments while optimizing for patient care.

Explore how Latica’s AI-powered platform can revolutionize your approach to life science research. Contact us today to learn more about our data resources and industry-leading platform.

175 Million Reasons to Be Excited: How Real-World Data Can Revolutionize Life Sciences

Author: Latica

The life sciences industry struggles to reconcile its innovative spirit with the slow, data-starved reality of bringing new treatments to patients. Traditional clinical trials, hampered by limited data access and restrictive settings, often lack the diversity and real-world experience needed to deliver unbiased results.

This is what Latica and our healthcare ecosystem have optimized a solution for. Imagine having access to anonymized information from over 175 million patient interactions, analyzed and enriched by the power of Artificial Intelligence (AI) and computer vision. This enables us to extract deeper insights from various sources, including electronic health records (EHRs), imaging, labs, videos, and more.

That’s the potential that researchers unlock with the Latica platform. With new data added daily, this rich tapestry keeps growing.

Latica goes beyond outdated data methods to supercharge life science and medtech research with real-world data (RWD):

Closing the Knowledge Gap: Real-world data can provide insights into how patients actually respond to treatments in their everyday lives, not just in a controlled setting. This can help bridge the gap between clinical trial data and real-world effectiveness.
Improved Trial Design: By analyzing RWD, researchers can predict and identify patient populations most likely to benefit from a new treatment, leading to more targeted and efficient clinical trials. This can save time and money, ultimately getting effective therapies to patients faster. Similarly, real-time access to unstructured data allows us to identify patients who meet technical inclusion / exclusion criteria on the spot, supporting site selection and patient recruitment
Unearthing Hidden Patterns: RWD allows researchers to analyze vast datasets, uncovering patterns and relationships that might be missed in smaller, controlled trials. This can lead to discoveries about drug interactions, treatment side effects, and even the identification of entirely new indications for existing medications.
Enhanced Patient Safety: By monitoring real-world use of medications and devices, researchers can proactively identify potential issues. This allows for quicker interventions when needed.
Personalized Medicine: RWD can be used to develop personalized medicine approaches by tailoring treatments to individual patients based on their unique genetic makeup, medical history, and lifestyle factors.

Data quality and standardization are important considerations, and patient privacy and ethics are paramount. However, the potential benefits of real-world data to improve healthcare for all are undeniable.

Here are some exciting possibilities for the future:

Faster development cycles for new drugs and devices
More effective and personalized treatments for patients
A more proactive approach to patient safety
A deeper understanding of disease progression and treatment response

The future of life sciences is awash with data. By harnessing the power of real-world data, researchers and developers can unlock a new era of medical discovery, ultimately leading to better health outcomes for all.

Explore how Latica’s AI-powered platform can revolutionize your approach to life science research. Contact us today to learn more about our data resources and industry-leading platform.